RASSF1 and thyroid gland carcinoma: In some studies, RASSF1 promoter inactivation has been detected in more than 30% of thyroid tumors, representing the most and frequent event in thyroid cancers [72, 73]; however, in some reports, no significant correlation between RASSF1 methylation and thyroid cancer risk was detected [68, 74–78].